23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018...
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017...
16:00 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2 , TACC1 , ZAK , ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Pim-1 (PIM1); Pim-2 (PIM2)

Cancer INDICATION: Multiple myeloma (MM) In vitro and mouse studies identified a quinazolinone-based inhibitor of PIM1 and PIM2 that could help treat MM. Chemical synthesis and in vitro testing of quinazolinone-pyrrolopyrrolone analogs yielded one compound...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Jasco Pharmaceuticals, Roswell Park Cancer Institute deal

Jasco and Roswell Park partnered to jointly conduct preclinical testing of Jasco's cancer compound JP-11646 , including pharmacokinetic and pharmacodynamics analysis. The project will utilize Roswell Park's Center for Drug Development. Jasco will fund the...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Jasco Pharmaceuticals preclinical data

In an animal xenograft model of MM, twice-daily 30 mg/kg oral JP-11646 inhibited tumor growth by 82% vs. vehicle-treated controls. In MM cell lines with chromosome translocations known for poor prognosis, JP-11646 increased apoptosis and...
07:00 , Sep 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-Hodgkin's lymphoma (NHL) Pim-2 (PIM2); eukaryotic translation initiation factor 4A1 (EIF4A1) Patient tissue and mouse studies suggest protein translation inhibitors could help treat chemoresistant PIM2-expressing...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Jasco Pharmaceuticals, North Carolina Central University deal

The biotech and university will collaborate to develop therapeutics for pancreatic cancer using Jasco's preclinical selective Pim-1 (PIM1) , PIM2 and PIM3 kinase inhibitors. Further terms were not disclosed. Jasco Pharmaceuticals LLC , Woburn, Mass....
08:00 , Nov 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Pim-1 (PIM1); PIM2; PIM3 In vitro and mouse studies identified PIM1-, PIM2- and PIM3-inhibiting benzothienopyrimidinone compounds that could help treat cancer. The compounds had...